MedTrace Logo

Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics

NCT03238885 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 538

Last updated 2019-02-04

No results posted yet for this study

Summary

This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.

Conditions

  • Locally Advanced Rectal Cancer

Interventions

DIAGNOSTIC_TEST

pelvic MR examination

All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.

Sponsors & Collaborators

  • Sun Ying-Shi

    lead OTHER

Principal Investigators

  • Ying-Shi Sun · Peking University Cancer Hospital & Institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-01
Primary Completion
2018-12-18
Completion
2019-01-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03238885 on ClinicalTrials.gov